Table 2 Patient characteristics of the three groups according to disease duration
From: Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study
|  | Disease duration 0–5 years n = 44 | Disease duration 6–13 years n = 43 | Disease duration 14–38 years n = 41 | P value |
|---|---|---|---|---|
Age (year), median (IQR) | 44.5 (31.8–60.3) | 44 (28–62) | 51 (43–60) | 0.162 |
Male/Female, n (%) | 30 (68.2)/14 (31.8) | 26 (60.5)/17 (39.5) | 21 (51.2)/20 (48.8) | 0.279 |
Disease duration (year), median (IQR) | 2 (1–4) | 8 (6–10) | 25 (18–28) | < 0.001 |
Disease extent, n (%) | Â | Â | Â | Â |
 Extensive colitis | 25 (56.8) | 32 (74.4) | 20 (48.8) | 0.085 |
 Left-sided colitis | 13 (29.5) | 9 (20.9) | 18 (43.9) |  |
 Proctitis | 6 (13.6) | 2 (4.7) | 3 (7.3) |  |
CAI (Rachmilewitz index), median (IQR) | 1 (0–4) | 1 (0–2) | 1 (0–3) | 0.398 |
MES, n (%) | Â | Â | Â | Â |
 MES 0 | 15 (34.1) | 17 (39.5) | 19 (46.3) | 0.683 |
 MES 1 | 15 (34.1) | 18 (41.9) | 12 (29.3) |  |
 MES 2 | 13 (29.5) | 8 (18.6) | 9 (22.0) |  |
 MES 3 | 1 (2.3) | 0 (0.0) | 1 (2.4) |  |
UCEIS, median (IQR) | 1 (0–3) | 2 (0–2) | 1 (0–3) | 0.662 |
Sum of MES, median (IQR) | 1 (0–4) | 1 (0–3) | 1 (0–2) | 0.576 |
FC (µg/g), median (IQR) | 628 (169–3515) | 428 (89–4420) | 223 (46–1060) | 0.253 |
FIT (ng/mL), median (IQR) | 50 (30–1145) | 125 (30–808) | 30 (30–699) | 0.767 |
Medication at study, n (%) | Â | Â | Â | Â |
 Oral 5-ASA | 25 (56.8) | 30 (69.8) | 33 (80.5) | 0.062 |
 Suppository steroids | 4 (9.1) | 1 (2.3) | 2 (4.9) | 0.374 |
 Systemic steroids | 5 (11.4) | 4 (9.3) | 4 (9.8) | 0.946 |
 Immunomodulators | 11 (25.0) | 17 (39.5) | 7 (17.1) | 0.063 |
 Advanced therapy | 15 (34.1) | 21 (48.8) | 11 (26.8) | 0.102 |